Xcout Intel
Brainsway
BrainsWay Ltd. is an international company that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a non-invasive treatment for depression, OCD, and smoking addiction. The company was founded in 2003 and has offices in the US and Jerusalem.
Subscribe to see Brainsway’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Brainsway at a glance
Brainsway is a medical - devices company headquartered in Jerusalem, Israel, founded in 2003. It is publicly listed (BWAY) with a market capitalisation of $489.1M. Xcout tracks 24 named people at Brainsway, including Hadar Levy (Chief Executive Officer).
Brainsway leadership
- Hadar LevyChief Executive Officer
- Ido MaromChief Financial Officer
- Gilead MoiseyevChief Technology Officer
- Naomi RozenfeldChief Marketing Officer
- Yiftach RothFounder & Chief Scientific Officer
- David ZacutCo-Founder & Vice-Chairman
18 more named people on record for Brainsway, with roles, board committees and tenure — see the full roster →
Brainsway competitors
A few of Brainsway's closest competitors — see the full list of competitors and alternatives →
NeuroStar provides advanced, non-invasive transcranial magnetic stimulation (TMS) treatments designed for patients suffering from depression. The company is headquartered in Malvern, Pennsylvania, and offers physician-recommended in-office therapy.
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
INSIGHTEC Ltd. is an Israeli medical device and global healthcare company headquartered in Tirat Carmel and Haifa, Israel, with additional presence in Miami. The firm develops advanced treatments such as Exablate Neuro for Parkinson's disease.
NeuroThera develops a clinical-grade transcranial photobiomodulation platform that delivers near-infrared laser light to targeted brain regions. The company's non-invasive technology aims to treat major neurological and psychiatric conditions, including major depressive disorder, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and stroke recovery.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Syqe Medical is a pharma-tech company that develops a precision inhalation platform designed to deliver central nervous system (CNS) drugs with pharmaceutical-grade accuracy. The company's technology features micro-dosing capabilities, consistent absorption technologies, and cloud-connected adherence tracking to optimize treatments for conditions such as diabetic peripheral neuropathic pain, PTSD, and insomnia.
Get Brainsway's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Brainsway in Xcout Intel
- 24 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access